Resources
BNET Resources
- sort by:
- Relevance
- Date
- Popularity
- Baby Born Deaf and Blind After Mom Took Botox Equivalent
- An Australian woman gave birth to a deaf and blind baby in 2005 after taking Dysport, a botulinum type A toxin similar to Allergan's Botox. Dysport is marketed down under by Ipsen. The event was reported to Australia's equivalent of the FDA, according to the Courier Mail: The...
- Blog posts 2009-01-05
Additional Resources
- Allergan Could Lose a Third of Botox Market With FDA's Approval of Medicis' Dysport
- The FDA has approved a competitor to Allergan's Botox. The new wrinkle-fighting drug will be marketed by Medicis as Dysport. (Medicis had intended to call it Reloxin, but apparently it's become Dysport.) Medicis partner Ipsen will market Dysport for cervical dystonia. by Jim Edwards
- Blog posts 2009-04-30
- Allergan Inc. Q2 2009 Earnings Call Transcript
- Question-and-Answer Session Operator Operator Instructions Our first question comes from Ken Cacciatore – Cowen and Co. Ken Cacciatore – Cowen and Co. Just a couple of questions, David on the Dysport launch anything about the early production that's surprising to you, or has it been as you...
- Earnings calls 2009-07-31
- Allergan's Q1 Nightmare: Profit Down; Black Box Warning on Botox Vindicates an Old Nemesis; "It's All Medicis' Fault!"
- Call it Allergan's worst week ever: Q1 2009 net income was down 58 percent on declining Botox sales; and then the FDA gave Botox a black box warning AND approved Medicis' competing wrinkle-killing drug, Dysport. Allergan's response? To blame it all on Medicis in a tangled set of statements that...
- Blog posts 2009-05-01
- Ipsen: FDA Accepts for Filing a Biologics License Application for Dysport® in Cervical Dystonia
- PARIS -- Regulatory News:
- Research articles 2008-01-31
- Ipsen Submits a Biologics License Application in Cervical Dystonia to the FDA for Dysport®
- PARIS -- Regulatory News:
- Research articles 2007-12-06
- Could Allergan's Reliance on Stars Hurt It in War With Medicis?
- In the vanity pharma war, Allergan continues to rely on celebrities while Medicis is relying more on price, and that could hurt Allergan. BNET noted that Medicis' Botox competitor, Dysport, would be priced lower than the leading brand when it was approved in April. by Jim Edwards
- Blog posts 2009-06-08
- Earnings Preview: Allergan
- Allergan AGN is expected to report Q3 earnings on Thursday, October 29 before the market open with a conference call scheduled for 11am ET. Guidance Analysts are looking for EPS of 70c on revenue of $1.08B. The consensus range is 67c-72c for EPS, and $1.05B-$1.11B for...
- External links 2009-10-28
- Allergan Q3 2009 Earnings Call Transcript
- Question-and-Answer SessionOperator Thank you. Operator Instructions. Our first question comes from Frank Pinkerton, SunTrust. Frank Pinkerton - SunTrust Robinson Humphrey Hey. First of all, Dave I believe you made a comment around Dysport expanding the market versus cannibalizing it. Do you have any data point that Jim gave us...
- Earnings calls 2009-10-29
- << Previous
- page 1 of 1
- Next >>
